Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats

Diabetes, Obesity and Metabolism

Volumn 13, Issue 12, 2011, Pages 1123-1129

  Zhao, M ^a   Li, Y ^a   Wang, J ^a   Ebihara, K ^a   Rong, X ^a   Hosoda, K ^a   Tomita, T ^a   Nakao, K ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II type 1 receptor; Azilsartan; Insulin; Obesity; Peroxisome proliferator activated receptor

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; ADIPONECTIN; AP2 PROTEIN; AZILSARTAN; FATTY ACID; GLUCOSE; INSULIN; PEPTIDES AND PROTEINS; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY ACID BLOOD LEVEL; FOOD INTAKE; GENE EXPRESSION; GENE TARGETING; GLUCOSE BLOOD LEVEL; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 80054004924     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01471.x     Document Type: Article

References (29)

1. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 2004; 110: 1507-1512.
2. Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
3. Negro R, Formoso G, Hassan H. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest 2006; 29: 957-961.
4. Aksnes TA, Seljeflot I, Torjesen PA, Höieggen A, Moan A, Kjeldsen SE. Improved insulin sensitivity by the angiotensin II-receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity. Metabolism 2007; 56: 1470-1477.
5. Nishimura H, Sanaka T, Tanihata Y, Naito T, Higuchi C, Otsuka K. Losartan elevates the serum high-molecular weight-adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism. Hypertens Res 2008; 31: 1611-1618.
6. Rong X, Li Y, Ebihara K et al. Irbesartan treatment up-regulates hepatic expression of PPARalpha and its target genes in obese Koletsky (fak/fak) rats: a link to amelioration of hypertriglyceridaemia. Br J Pharmacol 2010; 160: 1796-1807.
7. White WB, Weber MA, Sica D et al. Effects of the Angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57: 413-420.
8. Ojima M, Igata H, Tanaka M et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2010; 336: 801-808.
9. Iwai M, Chen R, Imura Y, Horiuchi M. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens 2007; 20: 579-586.
10. Takaya K, Ogawa Y, Hiraoka J et al. Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky rat. Nat Genet 1996; 14: 130-131.
11. Rong X, Li Y, Ebihara K et al. An adipose tissue-independent insulin-sensitizing action of telmisartan: a study in lipodystrophic mice. J Pharmacol Exp Ther 2009; 331: 1096-1103.
12. Rong X, Li Y, Ebihara K et al. Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice. Diabetologia 2010; 53: 1727-1731.
13. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004; 10: 355-361.
14. Sharma AM, Staels B. Peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 2007; 92: 386-395.
15. Cai XJ, Lister CA, Buckingham RE et al. Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and Zucker diabetic fatty rats and effects of rosiglitazone. Brain Res Mol Brain Res 2000; 77: 131-137.
16. Finegood DT, McArthur MD, Kojwang D et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001; 50: 1021-1029.
17. Reifel-Miller A, Otto K, Hawkins E et al. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. Mol Endocrinol 2005; 19: 1593-1605.
18. Seckl JR, Walker BR. Minireview: 11β-hydroxysteroid dehydrogenase type 1: a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001; 142: 1371-1376.
19. Livingstone DE, Jones GC, Smith K et al. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 2000; 141: 560-563.
20. Masuzaki H, Paterson J, Shinyama H et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-2170.
21. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC, Grino M. Expression of the mRNA coding for 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 2002; 87: 2701-2705.
22. Tomlinson JW, Walker EA, Bujalska IJ et al. 11β-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004; 25: 831-866.
23. Alberts P, Engblom L, Edling N et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002; 45: 1528-1532.
24. Alberts P, Nilsson C, Selen G et al. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 2003; 144: 4755-4762.
25. Wang SJ, Birtles S, de Schoolmeester J et al. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice. Diabetologia 2006; 49: 1333-1337.
26. Park JS, Rhee SD, Kang NS et al. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1, 1-dioxo-2H-1, 2-benzothiazine-2-yl-1-phenylethanone (KR-66344). Biochem Pharmacol 2011; 81: 1028-1035.
27. Kim J, Temple KA, Jones SA, Meredith KN, Basko JL, Brady MJ. Differential modulation of 3T3-L1 adipogenesis mediated by 11beta-hydroxysteroid dehydrogenase-1 levels. J Biol Chem 2007; 282: 11038-11046.
28. Arai N, Masuzaki H, Tanaka T et al. Ceramide and adenosine 5′-monophosphate-activated protein kinase are two novel regulators of 11beta-hydroxysteroid dehydrogenase type 1 expression and activity in cultured preadipocytes. Endocrinology 2007; 148: 5268-5277.
29. Berry C, Touyz R, Dominiczak AF, Webb RC, Johns DG. Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. Am J Physiol Heart Circ Physiol 2001; 281: H2337-2365.